IRINA DAUPHINEE: Open Payments
NPI 1417132259 · HANOVER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,987 in 97 payments from 10 companies in 2025. Trend: 2023 $6,282 · 2024 $3,211 · 2025 $4,987
Food & beverage: $4,987
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $962 |
| Otsuka America Pharmaceutical, Inc. | 19 | $897 |
| E.R. Squibb & Sons, L.L.C. | 12 | $761 |
| Teva Pharmaceuticals USA, Inc. | 13 | $676 |
| Janssen Pharmaceuticals, Inc | 10 | $546 |
| ABBVIE INC. | 7 | $369 |
| Axsome Therapeutics, Inc. | 3 | $256 |
| Alkermes, Inc. | 2 | $212 |
| Neurocrine BioSciences, Inc. | 2 | $195 |
| ACADIA Pharmaceuticals Inc | 2 | $111 |
Products named: CAPLYTA, REXULTI, COBENFY, UZEDY, INVEGA SUSTENNA, VRAYLAR, INGREZZA, Auvelity.
Industry payments across MA — which companies pay providers there.
